Key points are not available for this paper at this time.
Aspirin is one of the most widely used and commonly prescribed medications in the world. It was first approved by the US Food and Drug Administration (FDA) in 1985 for the secondary prevention of cardiovascular events in patients following an acute myocardial infarction (MI) (1) and continues to be prescribed widely for patients with and those at heightened risk for atherosclerotic cardiovascular disease (ACVD)-related events.
Kayse et al. (2016) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: